Volume Spike Investor

Human Genome Sciences Inc. (NASDAQ: HGSI) is going to be the top price leader this morning.  It and GlaxoSmithKline (GSK) have announced that the BENLYSTA study met the primary endpoint in BLISS-52, the first of two pivotal Phase III trials in patients with serologically active systemic lupus. HGSI shares closed at $3.32 Friday, yet the shares are north of $10.00 in early trading.  As of 7:53 AM EST we have seen 800,000 shares trade hands and the average volume is about 5.8 million shares. This will also be a 52-week high as the prior 52-week trading range was $0.45 to $8.00.

UPDATE at 8:53 AM EST: HGSI has traded 6.1 million shares and shares are now north of $11.00.

-JON OGG